Edition:
United States

Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

15.30USD
3:59pm EST
Change (% chg)

$0.27 (+1.80%)
Prev Close
$15.03
Open
$15.35
Day's High
$15.43
Day's Low
$15.28
Volume
2,957
Avg. Vol
5,505
52-wk High
$20.35
52-wk Low
$12.32

Chart for

About

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and... (more)

Overall

Beta: 0.97
Market Cap(Mil.): kr.2,816.82
Shares Outstanding(Mil.): 30.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 187.16 16.73
EPS (TTM): -- -- --
ROI: -- -0.71 35.60
ROE: -- -3.52 17.23

BRIEF-Zealand Pharma And Uniquest Collaborate To Develop Novel Drug Candidates

* REG-ZEALAND PHARMA AND UNIQUEST COLLABORATE TO DEVELOP NOVEL DRUG CANDIDATES FOR GASTROINTESTINAL DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 20 2018

BRIEF-Zealand Reports Royalty Revenue Of DKK 11.3 Mln For Q4 2017

* REG-ZEALAND REPORTS ROYALTY REVENUE FOR THE FOURTH QUARTER OF 2017

Feb 07 2018

Biotech Zealand Pharma bets on self-marketing over big pharma partnerships

GLOSTRUP, Denmark, Jan 30 Denmark's Zealand Pharma is pinning its strategy on rare disease drugs that the small biotech can market itself after seeing disappointing income from a diabetes drug marketed by partner Sanofi, its chief executive said.

Jan 30 2018

BRIEF-Zealand: Clinical Evidence Support Potential For Glepaglutide

* ZEALAND HAS COMPLETED A PHARMACOKINETIC (PK) STUDY WITH GLEPAGLUTIDE THAT CONFIRMS POTENTIAL FOR ONCE-WEEKLY DOSING

Jan 23 2018

BRIEF-Zealand Pharma Announces Progress To Phase 3 With Dasiglucagon For The Treatment Of Congenital Hyperinsulinism

* ZEALAND PHARMA ANNOUNCES PROGRESS TO PHASE 3 WITH DASIGLUCAGON FOR THE TREATMENT OF CONGENITAL HYPERINSULINISM IN FIRST HALF 2018

Jan 19 2018

BRIEF-Zealand Pharma Makes Initial USD 1.5 Mln Equity Investment In Beta Bionics

* ZEALAND PHARMA MAKES AN INITIAL USD 1.5 MILLION EQUITY INVESTMENT IN SERIES B OFFERING OF BETA BIONICS, INC.

Dec 21 2017

BRIEF-Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon

* ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES

Dec 07 2017

BRIEF-Zealand Pharma Q3 operating loss at DKK 38.2 mln ​

* ‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​

Nov 08 2017

BRIEF-Zealand reports royalty revenue Of DKK 10.3 mln for Q3

* REG- ZEALAND REPORTS ROYALTY REVENUE FOR THE THIRD QUARTER OF 2017

Nov 02 2017

BRIEF-Zealand Pharma granted orphan drug designation by FDA

* REG-U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME

Oct 24 2017

Earnings vs. Estimates